DESTINY-Gastric02: Trastuzumab Deruxtecan in Western Patients With HER2+ Advanced Gastric or GEJ Cancer With Progression Following First-line Trastuzumab-Containing Therapy

September 16-21, 2021; Virtual
In this single-arm phase II trial, second-line therapy with trastuzumab deruxtecan showed a response rate of 38% and durable responses following a trastuzumab-containing regimen in Western patients with HER2+ advanced gastric or GEJ cancer with no unexpected adverse events.
Format: Microsoft PowerPoint (.ppt)
File Size: 248 KB
Released: September 22, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Daiichi Sankyo, Inc.
Exelixis, Inc.
Ipsen Biopharmaceuticals, Inc.

Related Content

Experts discuss best practices in managing patients with hepatocellular carcinoma (HCC), from Clinical Care Options (CCO)

Richard S. Finn, MD Amit G. Singal, MD, MS Mark Yarchoan, MD Released: January 3, 2022

In this slideset from Clinical Care Options (CCO), experts discuss important factors in selecting regorafenib and TAS-102 for colorectal cancer (CRC)

Chiara Cremolini, MD, PhD person default Teresa Macarulla, MD Released: December 20, 2021

From Clinical Care Options (CCO), experts review key data in genitourinary, gastrointestinal, breast, and lung cancers presented at the ESMO 2021 congress

Eva M. Ciruelos, MD, PhD Karim Fizazi, MD, PhD Eric Van Cutsem, MD, PhD person default Vamsidhar Velcheti, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: December 15, 2021 Expired: December 14, 2022

Gain key clinical insights quickly with this short slideset from Clinical Care Options (CCO) on targeted and immunotherapies for HCC and BTCs

Richard S. Finn, MD Amit G. Singal, MD, MS Mark Yarchoan, MD Released: November 18, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings